Achieving a Better Outcome Through Limiting the Glioblastoma Clinical Target Volume

Summary

The objective of the BELGICA trial is to evaluate if radiotherapy could be given in a more focused manner in patients with glioblastoma in order to reduce side effects and improve quality of life. The glioblastoma (GBM) is the most common and aggressive tumour originating from the brain, affecting approximately 600 patients per year in Belgium. The treatment consists in surgical resection of the tumour (when feasible), followed by a combination of radiotherapy and chemotherapy. Despite multimodal treatment (surgery, radiotherapy, and chemotherapy), the life expectancy of patients with GBM remains limited, with an average survival of 12-18 months and only 5% of patients surviving more than 5 years. In addition to limited survival, most patients with GBM experience impaired quality of life, both because of the disease and treatments. Radiotherapy is a treatment where radiation is used to kill cancer cells. In GBM, radiotherapy is targeted at the tumour (or tumour bed if the tumour was resected) with a safety margin around it (the "Clinical Target Volume" or CTV) to account for potential microscopic spread of the tumour. The downside of this safety margin is that a substantial amount of brain tissue is irradiated, which can lead to treatment toxicity. Reducing the CTV margin would enable to decrease the volume of brain being irradiated and could thereby allow to reduce the side effects of brain irradiation. The BELGICA trial (Achieving a BEtter outcome through Limiting the GlIoblastoma Clinical tArget volume) is a national multicentre trial which will evaluate if reducing the irradiation volume in glioblastoma is safe and allows for lowering side effects and improving quality of life.

Interventions

• Radiotherapy (CTV=10mm) · RADIATION

  Radiotherapy with reduced irradiation volume CTV=10mm

• Radiotherapy (CTV=15mm) · RADIATION

  Radiotherapy with standard irradiation volume CTV=15mm

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

* Participants capable of giving informed consent
* Age \>= 18 y.o.
* WHO performance status 0-2
* Newly diagnosed glioblastoma (Histologically proven glioblastoma per WHO 2021 classification based on biopsy or resection )
* Indication of chemoradiotherapy confirmed by multidisciplinary tumour board

Exclusion Criteria:

* Participation in a competing trial
* Known contraindication to undergo MRI scans

Sites (23)

• Olv Azorg, Aalst, Belgium · NOT_YET_RECRUITING
• EpiCURA, Baudour, Belgium · RECRUITING
• AZ Sint Jan, Bruges, Belgium · RECRUITING
• Institut Jules Bordet, Brussels, Belgium · NOT_YET_RECRUITING
• UZ Brussel, Brussels, Belgium · NOT_YET_RECRUITING
• Cliniques universitaires Saint-Luc, Brussels, Belgium · RECRUITING
• Ziekenhuis Oost-Limburg (ZOL), Genk, Belgium · RECRUITING
• AZ Sint-Lucas, Ghent, Belgium · RECRUITING
• UZ Gent, Ghent, Belgium · NOT_YET_RECRUITING
• Grand Hôpital de Charleroi, Gilly, Belgium · RECRUITING
• JESSA Ziekenhuis, Hasselt, Belgium · RECRUITING
• AZ Groeninge, Kortrijk, Belgium · RECRUITING
• Chu Helora, La Louvière, Belgium · RECRUITING
• UZ Leuven, Leuven, Belgium · RECRUITING
• CHU Liège, Liège, Belgium · RECRUITING
• AZ Sint Maarten, Mechelen, Belgium · RECRUITING
• Hôpital André Vésale - HUmani, Montigny-le-Tilleul, Belgium · RECRUITING
• CH Mouscron, Mouscron, Belgium · NOT_YET_RECRUITING
• CHU UCL Namur - Sainte Elisabeth, Namur, Belgium · RECRUITING
• AZ Delta, Roeselare, Belgium · RECRUITING
• Cliniques de l'Europe, Uccle, Belgium · RECRUITING
• CHR Verviers, Verviers, Belgium · RECRUITING
• ZAS Augustinus, Wilrijk, Belgium · RECRUITING